Close Menu

NEW YORK (GenomeWeb) – Abbott said Wednesday that its fourth quarter diagnostic revenues grew 3 percent year over year on a reported basis and 7 percent on an organic basis to $1.96 billion from $1.91 billion in the year-ago period.

For the three months ended Dec. 31, 2018, Abbott reported worldwide revenues of $7.77 billion, up 2 percent from $7.59 billion a year ago, but lower than the average Wall Street estimate of $7.82 billion. Sales increased 6 percent year over year on an organic basis.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.